| Date | Action | Shares | Price | Value | Owned After |
|---|---|---|---|---|---|
| May 1, 2026 | Conversion(C) | 3.3M | — | — | 3.3M |
| May 1, 2026 | Buy(P) | 556K | $18.00 | $10.0M | 3.9M |
| Date | Action | Shares | Price | Value | Owned After |
|---|---|---|---|---|---|
| May 1, 2026 | Conversion(C) | 18.0M | — | $0 | 0 |
| May 1, 2026 | Conversion(C) | 2.0M | — | $0 | 0 |
| May 1, 2026 | Conversion(C) | 25.9M | — | $0 | 0 |
| May 1, 2026 | Conversion(C) | 5.6M | — | $0 | 0 |
| May 1, 2026 | Conversion(C) | 12.6M | — | $0 | 0 |
Parsed from a single SEC EDGAR Form 4 filing (accession 0001388325-26-000021) within minutes of acceptance. Every field above traces to the original document. Verify it directly:
Connected pages for Avalyn Pharma Inc.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.